Crohn's Disease Pipeline Report, 2024 Updates : In-depth Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, and Growth Prospects | AstraZeneca, Immunic, Suzhou Connect Biopharmaceuticals, Pfizer, Bristol-Myers Squibb

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Crohn's Disease pipeline constitutes 90+ key companies continuously working towards developing 90+ Crohn's Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Crohn's Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Crohn's Disease Market.

The Crohn's Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Crohn's Disease Pipeline Report: https://www.delveinsight.com/sample-request/crohns-disease-cd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Crohn's Disease treatment therapies with a considerable amount of success over the years.
• Crohn's Disease companies working in the treatment market are Morphic Therapeutic, Orchard Therapeutics, Thetis Pharmaceuticals, AstraZeneca, Immunic, Suzhou Connect Biopharmaceuticals, Pfizer, Bristol-Myers Squibb, Eisai Inc, Janssen Pharmaceutical, Eli Lilly and Company, Gilead Sciences, RedHill Biopharma, Celgene Corporation, AstraZeneca, and others, are developing therapies for the Crohn's Disease treatment
• Emerging Crohn's Disease therapies in the different phases of clinical trials are- MORF 057, OTL-104, TP-317, AZD 7798, IMU 856, CBP-307, PF-06651600, Deucravacitinib, E6011, Guselkumab, Mirikizumab, Filgotinib, RHB-104, Ozanimod, Brazikumab, and others are expected to have a significant impact on the Crohn's Disease market in the coming years.
• In October 2023, Eli Lilly and Company (NYSE: LLY) disclosed that mirikizumab, an experimental interleukin-23p19 antagonist, achieved positive results by meeting both co-primary and all significant secondary endpoints when compared to a placebo in the VIVID-1 Phase 3 trial. This study aimed to assess the safety and effectiveness of mirikizumab in adults dealing with moderately to severely active Crohn's disease. The trial, which was conducted in a double-blind, treat-through manner, involved arms for mirikizumab, placebo, and an active control group receiving ustekinumab.
• In July 2023, Telavant initiated its clinical trial to investigate its treatment candidate RVT-3101 for Crohn's disease (CD) and administered the first dose to a patient. The TAHOE study (NCT05910528) is a global, randomized, double-blind trial expected to enroll 105 participants with moderate to severely active CD. Telavant, a subsidiary of Roivant, is assessing two doses of RVT-3101 given monthly, with patient evaluation at week 14. The primary endpoint of the study is the proportion of participants achieving clinical remission based on the Crohn's Disease Activity Index (CDAI). The secondary outcome measures the proportion of participants achieving an endoscopic response.
• In May 2023, For those with moderate to severe active Crohn's disease who did not respond well to or were intolerant of one or more tumour necrosis factor blockers, the FDA has approved Rinvoq (upadacitinib). The first oral medicine for the management of Crohn's disease that has received FDA approval is called Rinvoq.
• In February 2023, Galapagos NV disclosed the primary findings from DIVERSITY, a Phase 3 trial conducted worldwide to assess the safety and effectiveness of filgotinib, administered once daily at doses of 100mg or 200mg, for both induction and maintenance therapy in patients with moderate to severe Crohn's disease (CD), who were either new to biologic treatments or had prior experience with them. The trial's co-primary endpoints, evaluated at Week 10 and Week 58, included achieving clinical remission based on Patient Reported Outcome (PRO-2) and demonstrating endoscopic response as per the Simple Endoscopic Score for Crohn's Disease (SES-CD).

Crohn's Disease Overview
A long-lasting inflammatory condition of the gastrointestinal tract, Crohn's disease causes the intestinal wall's serosa and mucosa to become inflamed. It is a chronic condition that recurs frequently. Crohn's disease may at first just affect a small portion of the digestive tract, but it has the potential to spread widely.

Get a Free Sample PDF Report to know more about Crohn's Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/crohns-disease-cd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Crohn's Disease Drugs Under Different Phases of Clinical Development Include:
• MORF 057: Morphic Therapeutic
• OTL-104: Orchard Therapeutics
• TP-317: Thetis Pharmaceuticals
• AZD 7798: AstraZeneca
• IMU 856: Immunic
• CBP-307: Suzhou Connect Biopharmaceuticals
• PF-06651600: Pfizer
• Deucravacitinib: Bristol-Myers Squibb
• E6011: Eisai Inc
• Guselkumab: Janssen Pharmaceutical
• Mirikizumab: Eli Lilly and Company
• Filgotinib: Gilead Sciences
• RHB-104: RedHill Biopharma
• Ozanimod: Celgene Corporation
• Brazikumab: AstraZeneca

Crohn's Disease Route of Administration
Crohn's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Crohn's Disease Molecule Type
Crohn's Disease Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Crohn's Disease Pipeline Therapeutics Assessment
• Crohn's Disease Assessment by Product Type
• Crohn's Disease By Stage and Product Type
• Crohn's Disease Assessment by Route of Administration
• Crohn's Disease By Stage and Route of Administration
• Crohn's Disease Assessment by Molecule Type
• Crohn's Disease by Stage and Molecule Type
DelveInsight's Crohn's Disease Report covers around 90+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Crohn's Disease product details are provided in the report. Download the Crohn's Disease pipeline report to learn more about the emerging Crohn's Disease therapies
https://www.delveinsight.com/sample-request/crohns-disease-cd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Crohn's Disease Therapeutics Market include:
Key companies developing therapies for Crohn's Disease are - Janssen, RedHill Biopharma, Amgen, Pfizer, Prometheus Biosciences, AgomAb Therapeutics, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, HAV Vaccines Ltd, Enzo Biochem Inc., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Pfizer, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, AstraZeneca, Mesoblast, Soligenix, Immunic, Pfizer, Atlantic Healthcare, 4D Pharma, and others.

Crohn's Disease Pipeline Analysis:
The Crohn's Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Crohn's Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Crohn's Disease Treatment.
• Crohn's Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Crohn's Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Crohn's Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Crohn's Disease drugs and therapies
https://www.delveinsight.com/sample-request/crohns-disease-cd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Crohn's Disease Pipeline Market Drivers
• High prevalence of Crohn's Disease, increase in Drug Development for Crohn's treatment, change in lifestyle patterns are some of the important factors that are fueling the Crohn's Disease Market.

Crohn's Disease Pipeline Market Barriers
• However, lack of early diagnosis of the disease, high cost associated with the treatment and other factors are creating obstacles in the Crohn's Disease Market growth.

Scope of Crohn's Disease Pipeline Drug Insight
• Coverage: Global
• Key Crohn's Disease Companies: Morphic Therapeutic, Orchard Therapeutics, Thetis Pharmaceuticals, AstraZeneca, Immunic, Suzhou Connect Biopharmaceuticals, Pfizer, Bristol-Myers Squibb, Eisai Inc, Janssen Pharmaceutical, Eli Lilly and Company, Gilead Sciences, RedHill Biopharma, Celgene Corporation, AstraZeneca, and others
• Key Crohn's Disease Therapies: MORF 057, OTL-104, TP-317, AZD 7798, IMU 856, CBP-307, PF-06651600, Deucravacitinib, E6011, Guselkumab, Mirikizumab, Filgotinib, RHB-104, Ozanimod, Brazikumab, and others
• Crohn's Disease Therapeutic Assessment: Crohn's Disease current marketed and Crohn's Disease emerging therapies
• Crohn's Disease Market Dynamics: Crohn's Disease market drivers and Crohn's Disease market barriers

Request for Sample PDF Report for Crohn's Disease Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/crohns-disease-cd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Crohn's Disease Report Introduction
2. Crohn's Disease Executive Summary
3. Crohn's Disease Overview
4. Crohn's Disease- Analytical Perspective In-depth Commercial Assessment
5. Crohn's Disease Pipeline Therapeutics
6. Crohn's Disease Late Stage Products (Phase II/III)
7. Crohn's Disease Mid Stage Products (Phase II)
8. Crohn's Disease Early Stage Products (Phase I)
9. Crohn's Disease Preclinical Stage Products
10. Crohn's Disease Therapeutics Assessment
11. Crohn's Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Crohn's Disease Key Companies
14. Crohn's Disease Key Products
15. Crohn's Disease Unmet Needs
16 . Crohn's Disease Market Drivers and Barriers
17. Crohn's Disease Future Perspectives and Conclusion
18. Crohn's Disease Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Crohn's Disease Market https://www.delveinsight.com/report-store/crohns-disease-cd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Crohn's Disease-Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Crohn's Disease Epidemiology https://www.delveinsight.com/report-store/crohns-disease-cd-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Crohn's Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Iga Nephropathy Market
https://www.delveinsight.com/report-store/iga-nephropathy-market
DelveInsight's "IgA Nephropathy Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of the IgA Nephropathy, historical and forecasted epidemiology as well as the IgA Nephropathy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China.

Vutrisiran Market
https://www.delveinsight.com/report-store/vutrisiran-market
DelveInsight's "Vutrisiran Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Vutrisiran, historical and forecasted epidemiology as well as the Vutrisiran market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Gastroesophageal Reflux Disease Market
https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market
DelveInsight's "Gastroesophageal Reflux Disease (GERD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Gastroesophageal Reflux Disease (GERD), historical and forecasted epidemiology as well as the Gastroesophageal Reflux Disease (GERD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Cerebral Palsy Market
https://www.delveinsight.com/report-store/cerebral-palsy-market
DelveInsight's 'Cerebral Palsy Market Insights, Epidemiology, and Market Forecast 2032' report delivers an in-depth understanding of cerebral palsy, historical and forecasted epidemiology as well as cerebral palsy market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Granulomatosis With Polyangiitis Market
https://www.delveinsight.com/report-store/granulomatosis-with-polyangiitis-market
DelveInsight's "Granulomatosis With Polyangiitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Granulomatosis With Polyangiitis, historical and forecasted epidemiology as well as the Granulomatosis With Polyangiitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Hemophilia A Market
https://www.delveinsight.com/report-store/hemophilia-a2030-market
DelveInsight's "Hemophilia A Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Hemophilia A, historical and forecasted epidemiology as well as the Hemophilia A market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Graft Versus Host Disease Market https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market
DelveInsight's "Graft Versus Host Disease (GvHD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Graft Versus Host Disease, historical and forecasted epidemiology as well as the Graft Versus Host Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Hemorrhoids Market
https://www.delveinsight.com/report-store/hemorrhoids-market
DelveInsight's "Hemorrhoids Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hemorrhoids, historical and forecasted epidemiology as well as the Hemorrhoids market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Asthma Market
https://www.delveinsight.com/report-store/asthma-market
DelveInsight's "Asthma - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Asthma market trends in the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Myelodysplastic Syndrome Market
https://www.delveinsight.com/report-store/myelodysplastic-syndrome-market
DelveInsight's "Myelodysplastic Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Myelodysplastic Syndrome, historical and forecasted epidemiology as well as the Myelodysplastic Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.